Abbvie Inc (ABBV)

$232.83 +2.64 (1.15%)
Market Cap 406.64B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 22.09
Forward PE 19.47
Profit Margin 7.59%
Debt to Equity Ratio -510.73
Volume 4,901,000
Avg Vol 5,560,354
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 56%
Beta 0.51
Analysts Strong Sell
Price Target $233.48

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
trading_momentum_x
trading_momentum_x Oct. 8 at 3:06 AM
$TSLA $AMD $PYPL $RKLB $ABBV Huge profits
0 · Reply
Garibs
Garibs Oct. 8 at 2:24 AM
$ABBV swing December calls, $EBAY swinging December calls
0 · Reply
Masonato
Masonato Oct. 8 at 2:07 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 8 at 2:01 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 8 at 1:56 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 7 at 9:23 PM
$ABBV https://finviz.com/news/185412/3-dividend-stocks-to-double-up-on-right-now
0 · Reply
TheStockTraderHub
TheStockTraderHub Oct. 7 at 8:01 PM
$ABBV UNUSUAL CALL BUYER into close today 🐋
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 7 at 7:15 PM
Enter: $ABBV OCT 31 2025 $235 CALLS Buy in Price: $5.85 - $5.95 Take Profit: $13.28 Stop Bleeding: $5.15 ROI Potential: 127% Exit Within: 190 Minutes https://moneygroup.us/alerts
0 · Reply
_Spartans
_Spartans Oct. 7 at 4:00 PM
$ABBV $UROY $HYPD $PD How much volume do it think it takes to halt NITO up? NITO has not even one million shares float and recent merger news. Hoping for a 400% run on NITO!
0 · Reply
RS_CAP_CA
RS_CAP_CA Oct. 7 at 2:26 PM
$SPRB next runner will be $XLO (look at who owns this stock $GILD $ABBV https://whalewisdom.com/stock/xlo-2
0 · Reply
Latest News on ABBV
My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 1 day ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ALVO AMGN ARKG AZN BIIB BMY GILD

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

Oct 6, 2025, 9:00 AM EDT - 1 day ago

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

AbbVie expects $2.7 billion R&D charge in third quarter

Oct 3, 2025, 4:16 PM EDT - 4 days ago

AbbVie expects $2.7 billion R&D charge in third quarter

AbbVie: Wins Accumulating While We Wait For Next BD Steps

Oct 3, 2025, 11:05 AM EDT - 4 days ago

AbbVie: Wins Accumulating While We Wait For Next BD Steps

ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 5 days ago

ABBV Stock vs. Eli Lilly & Merck

LLY MRK

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Oct 2, 2025, 8:00 AM EDT - 5 days ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Natrelle® Awarded Supplier Agreement from Vizient

Oct 1, 2025, 8:00 AM EDT - 6 days ago

Natrelle® Awarded Supplier Agreement from Vizient

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

Sep 30, 2025, 3:00 PM EDT - 7 days ago

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Sep 30, 2025, 8:00 AM EDT - 7 days ago

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Sep 29, 2025, 7:30 PM EDT - 8 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

Sep 29, 2025, 12:00 PM EDT - 8 days ago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

AbbVie to launch ovarian cancer drug in UK at the same list price as US

Sep 29, 2025, 9:11 AM EDT - 8 days ago

AbbVie to launch ovarian cancer drug in UK at the same list price as US

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

Sep 29, 2025, 9:00 AM EDT - 8 days ago

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

AbbVie For Healthy Dividend Growth

Sep 27, 2025, 7:00 AM EDT - 10 days ago

AbbVie For Healthy Dividend Growth

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

Sep 26, 2025, 4:50 PM EDT - 11 days ago

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

AMGN LLY MRK

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Sep 26, 2025, 1:47 PM EDT - 11 days ago

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

AMGN GILD LLY MRK MRNA PFE

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

Sep 26, 2025, 12:21 PM EDT - 11 days ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

LLY MRK PFE BIIB BMY

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

Sep 26, 2025, 8:45 AM EDT - 11 days ago

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists

Sep 25, 2025, 11:53 AM EDT - 12 days ago

AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists

Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

Sep 25, 2025, 5:00 AM EDT - 12 days ago

Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

These Dividend Stocks Have Big Yields and Are Beating the Odds

Sep 23, 2025, 2:47 PM EDT - 14 days ago

These Dividend Stocks Have Big Yields and Are Beating the Odds

ABT DGRO SDY VIG

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

Sep 23, 2025, 5:00 AM EDT - 14 days ago

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech

Sep 22, 2025, 3:37 PM EDT - 15 days ago

These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech

AAPL AMZN AVGO COST GOOG GOOGL HD

Calls of the Day: Netflix, Disney, Walmart and AbbVie

Sep 17, 2025, 1:48 PM EDT - 20 days ago

Calls of the Day: Netflix, Disney, Walmart and AbbVie

DIS NFLX WMT

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Sep 17, 2025, 7:52 AM EDT - 20 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

MDT PINC

AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.

Sep 12, 2025, 9:57 AM EDT - 25 days ago

AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.

AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

Sep 11, 2025, 12:25 PM EDT - 26 days ago

AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

AbbVie in Settlement With Generic Drugmakers on Rinvoq

Sep 11, 2025, 12:17 PM EDT - 26 days ago

AbbVie in Settlement With Generic Drugmakers on Rinvoq

Why Is AbbVie Stock Trading Higher On Thursday?

Sep 11, 2025, 9:55 AM EDT - 26 days ago

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie: What's Happening With ABBV Stock?

Sep 11, 2025, 9:45 AM EDT - 26 days ago

AbbVie: What's Happening With ABBV Stock?

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

Sep 10, 2025, 1:03 PM EDT - 27 days ago

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

AZN GSK NVO NVS SNY AMGN LLY

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 1:46 PM EDT - 4 weeks ago

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

Sep 9, 2025, 8:00 AM EDT - 4 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 4 weeks ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

VEEV VRTX VST

AbbVie Declares Quarterly Dividend

Sep 5, 2025, 9:07 AM EDT - 4 weeks ago

AbbVie Declares Quarterly Dividend

Global drugmakers rush to boost US presence as tariff threat looms

Sep 3, 2025, 2:09 PM EDT - 4 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD JNJ LLY MRK

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sep 3, 2025, 8:30 AM EDT - 4 weeks ago

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 5 weeks ago

AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

How To Invest $100,000 In A Near-Perfect Strategy Portfolio

Aug 30, 2025, 8:05 AM EDT - 5 weeks ago

How To Invest $100,000 In A Near-Perfect Strategy Portfolio

ADX BME CVX EOS FDVV HD JEPQ

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

Aug 29, 2025, 12:37 PM EDT - 5 weeks ago

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.

Aug 28, 2025, 2:41 PM EDT - 5 weeks ago

Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.

JNJ LLY XLV

Best Dividend Aristocrats For September 2025

Aug 27, 2025, 2:09 PM EDT - 5 weeks ago

Best Dividend Aristocrats For September 2025

ABT ADM ADP AFL ALB AMCR AOS

AbbVie: Plenty Of Positives

Aug 26, 2025, 1:24 PM EDT - 6 weeks ago

AbbVie: Plenty Of Positives

AbbVie Is A Top Biotech Pick

Aug 25, 2025, 9:18 AM EDT - 6 weeks ago

AbbVie Is A Top Biotech Pick

AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion

Aug 25, 2025, 9:09 AM EDT - 6 weeks ago

AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Aug 25, 2025, 8:59 AM EDT - 6 weeks ago

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Best Dividend Kings: August 2025

Aug 24, 2025, 10:13 PM EDT - 6 weeks ago

Best Dividend Kings: August 2025

ABM ABT ADM AWR BDX BKH CINF

AbbVie Investors Beware: Strong Growth Potential, Rising Risks

Aug 23, 2025, 10:31 AM EDT - 6 weeks ago

AbbVie Investors Beware: Strong Growth Potential, Rising Risks

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

Aug 21, 2025, 8:30 AM EDT - 6 weeks ago

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

AbbVie Completes Acquisition of Capstan Therapeutics

Aug 19, 2025, 8:55 AM EDT - 7 weeks ago

AbbVie Completes Acquisition of Capstan Therapeutics

trading_momentum_x
trading_momentum_x Oct. 8 at 3:06 AM
$TSLA $AMD $PYPL $RKLB $ABBV Huge profits
0 · Reply
Garibs
Garibs Oct. 8 at 2:24 AM
$ABBV swing December calls, $EBAY swinging December calls
0 · Reply
Masonato
Masonato Oct. 8 at 2:07 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 8 at 2:01 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 8 at 1:56 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 7 at 9:23 PM
$ABBV https://finviz.com/news/185412/3-dividend-stocks-to-double-up-on-right-now
0 · Reply
TheStockTraderHub
TheStockTraderHub Oct. 7 at 8:01 PM
$ABBV UNUSUAL CALL BUYER into close today 🐋
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 7 at 7:15 PM
Enter: $ABBV OCT 31 2025 $235 CALLS Buy in Price: $5.85 - $5.95 Take Profit: $13.28 Stop Bleeding: $5.15 ROI Potential: 127% Exit Within: 190 Minutes https://moneygroup.us/alerts
0 · Reply
_Spartans
_Spartans Oct. 7 at 4:00 PM
$ABBV $UROY $HYPD $PD How much volume do it think it takes to halt NITO up? NITO has not even one million shares float and recent merger news. Hoping for a 400% run on NITO!
0 · Reply
RS_CAP_CA
RS_CAP_CA Oct. 7 at 2:26 PM
$SPRB next runner will be $XLO (look at who owns this stock $GILD $ABBV https://whalewisdom.com/stock/xlo-2
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 7 at 2:12 PM
$ABBV if the people that work for you are 🤡s ? That means you are running a circus 🎪 ?
0 · Reply
Masonato
Masonato Oct. 7 at 2:11 PM
$ABBV https://www.fool.com/investing/2025/10/07/3-dividend-stocks-to-double-up-on-right-now/?source=djc&utm_source=djc&utm_medium=feed&utm_campaign=article&referring_guid=ffce5c22-eb9d-44d1-8825-2117acebd644&mod=mw_quote_news
0 · Reply
Masonato
Masonato Oct. 7 at 12:55 PM
$ABBV https://finviz.com/news/185412/3-dividend-stocks-to-double-up-on-right-now
0 · Reply
Quantumup
Quantumup Oct. 7 at 12:37 PM
Guggenheim reiterated $SYRE Buy-$65-Top Pick after hosting a dinner at UEGW with investors and SYRE's CEO (Cameron Turtle) and CMO (Sheldon Sloan). $JNJ $ABBV Guggenheim said in its note to investors:
0 · Reply
Thespartantrades
Thespartantrades Oct. 7 at 11:55 AM
$ABBV $OPEN $QBTS $UNH Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
trading_momentum_x
trading_momentum_x Oct. 7 at 11:54 AM
$V $PG $SBET $ABBV $RKLB Let's fuckin' gooooo!
0 · Reply
Masonato
Masonato Oct. 7 at 2:03 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 7 at 2:03 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 7 at 2:02 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 7 at 2:01 AM
$ABBV
0 · Reply
Masonato
Masonato Oct. 7 at 2:00 AM
$ABBV
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 12:35 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABBV Current Share Price: $229.82 Contracts: $ABBV October 16, 2026 $230 Calls Scale in: $23.83- $29.12 Scale out: $37.06-$47.66 Can Easily Capture: 60% ROI Blended DTE: 375 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply